Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD
Recruiting
The purpose of this randomized, double-blind, placebo-controlled study is to assess the efficacy of BIA 28-6156 over placebo in delaying clinical meaningful motor progression over 78 weeks in subjects with Parkinson's disease who have a pathogenic variant in the glucocerebrosidase 1 (GBA1) gene (GBA-PD).
Gender:
All
Ages:
Between 35 years and 80 years
Trial Updated:
11/22/2023
Locations: Mayo Clinic, Rochester, Minnesota +1 locations
Conditions: Parkinson's Disease
A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease
Recruiting
This study investigates the safety and tolerability of drug IkT-148009 in untreated Parkinson's disease volunteers (30 to 80 years old). It also looks at the pharmacokinetics of IkT-148009 in the body and evaluates the effect of IkT-148009 on motor and non-motor features of the disease. This 12 week study is designed to be 3:1 randomized across 3 doses of IkT-148009 or placebo. Each participant will self-administer one of 3 doses or placebo of IkT-148009 once daily (QD) with food for 12 weeks. F... Read More
Gender:
All
Ages:
Between 30 years and 80 years
Trial Updated:
11/17/2023
Locations: Neurology, Golden Valley, Minnesota
Conditions: Parkinson Disease
Automated Imaging Differentiation of Parkinsonism
Recruiting
The purpose of this study is to test the performance of the AID-P across 21 sites in the Parkinson Study Group. Each site will perform imaging, clinical scales, diagnosis, and will upload the data to the web-based software tool. The clinical diagnosis will be blinded to the diagnostic algorithm and the imaging diagnosis will be compared to the movement disorders trained neurologist diagnosis.
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
11/13/2023
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Parkinson Disease, Multiple System Atrophy, Parkinson Variant, Progressive Supranuclear Palsy
A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive Impairment
Recruiting
The primary purpose of this study is to evaluate the effect of SAGE-718 on cognitive performance in participants with Parkinson's disease mild cognitive impairment (PD-MCI).
Gender:
All
Ages:
Between 50 years and 75 years
Trial Updated:
11/02/2023
Locations: Sage Investigational Site, Bloomington, Minnesota
Conditions: Parkinson Disease, Cognitive Dysfunction
Altropane Dose for Imaging Patients With Suspected Parkinson's Disease
Recruiting
Previous studies showed that a dose of 8 millicuries of Altropane was appropriate for imaging patients with suspected Parkinson's disease. This study will determine if a lower dose (5 millicuries) would suffice.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/01/2023
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Parkinson Disease, Movement Disorders
Multiple Objective Particle Swarm Optimization Postural Instability Gait Disorder
Recruiting
Sixty patients will be enrolled in this study who are treated for Parkinson's disease (PD) with bilateral deep brain stimulation of subthalamic nucleus (STN) or globus pallidus (GP), who have a pre- operative 7 Tesla MRI including diffusion tensor imaging for tractography and a postoperative head CT for electrode localization, and in whom at least 3 months have passed since activation of their neurostimulators, for stabilization of clinical stimulator settings. Using their MRI and CT, the invest... Read More
Gender:
All
Ages:
Between 18 years and 89 years
Trial Updated:
10/30/2023
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Parkinson Disease
Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study in patients with a diagnosis of Parkinson's Disease consistent with the UK Parkinson's Disease Society (UKPDS) Brain Bank diagnostic criteria, who are experiencing wearing off symptoms and levodopa-induced dyskinesia.
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
10/20/2023
Locations: Clinical Site, Golden Valley, Minnesota
Conditions: Parkinson Disease
Effects of Pallidal Deep Brain Stimulation Location on Motor Impairment in Parkinson's Disease
Recruiting
This protocol will characterize the effects of deep brain stimulation (DBS) location (both adverse and beneficial) on motor signs in people with Parkinson's disease (PD). This information can be used to inform future DBS protocols to tailor stimulation to the specific needs of a patient. If targeted dorsal GP stimulation is shown to significantly improve motor features that are typically resistant to dopamine replacement therapy, these experiments will likely have major impact on clinical practi... Read More
Gender:
All
Ages:
Between 18 years and 89 years
Trial Updated:
10/05/2023
Locations: University Of Minnesota, Minneapolis, Minnesota
Conditions: Parkinson's Disease
Natural History Study of Synucleinopathies
Recruiting
Synucleinopathies are a group of rare diseases associated with worsening neurological deficits and the abnormal accumulation of the protein α-synuclein in the nervous system. Onset is usually in late adulthood at age 50 or older. Usually, synucleinopathies present clinically with slowness of movement, coordination difficulties or mild cognitive impairment. Development of these features indicates that abnormal alpha-synuclein deposits have destroyed key areas of the brain involved in the control... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
09/26/2023
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Patients With Synucleinopathies, Neurogenic Orthostatic Hypotension, Pure Autonomic Failure, REM Sleep Behavior Disorder, Parkinson Disease, Dementia With Lewy Bodies, Multiple System Atrophy, Shy-Drager Disease
DBS and Sleep Outcomes
Recruiting
The objective of this study is to describe how activation of distinct pathways in and around the subthalamic nucleus (STN) and internal segment of the globus pallidus (GPi) correlate to changes in sleep outcomes in movement disorders patients after deep brain stimulation (DBS) surgery targeting these structures.
Gender:
All
Ages:
21 years and above
Trial Updated:
09/13/2023
Locations: University Of Minnesota, Minneapolis, Minnesota
Conditions: Deep Brain Stimulation, Parkinson's Disease and Parkinsonism, Dystonia
Aim 3 Particle Swarm Optimization PIGD
Recruiting
In Parkinson's disease (PD) patients undergoing standard-of-care Deep Brain Stimulation (DBS) therapy, to compare the effect on Parkinson's symptoms of two different neurostimulator settings designed to differ from each other as much as possible with respect to how much they activate two different neuroanatomical structures: the axonal pathway from Globus Pallidus (GP) to Pedunculopontine Nucleus (PPN), and the axonal pathway from PPN to GP.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
08/29/2023
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Parkinson's Disease and Parkinsonism
Neuroplasticity in RBD
Recruiting
REM sleep behavior disorder is a parasomnia that reflects the presence of alpha-synucleinopathy in the brain and is highly predictive of eventual phenoconversion to Parkinson's disease, dementia with Lewy bodies, or multiple system atrophy over the course of years to decades. Neuroplastic adaptations in the brain during the prodromal stage of disease are thought to mask the expression of motor and non-motor signs and may substantially delay diagnosis during a potentially critical time window. Th... Read More
Gender:
All
Ages:
Between 21 years and 75 years
Trial Updated:
07/31/2023
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Parkinson